178 related articles for article (PubMed ID: 30254080)
1. Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.
Thorek DLJ; Ku AT; Mitsiades N; Veach D; Watson PA; Metha D; Strand SE; Sharma SK; Lewis JS; Abou DS; Lilja HG; Larson SM; McDevitt MR; Ulmert D
Clin Cancer Res; 2019 Jan; 25(2):881-891. PubMed ID: 30254080
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of hK2 targeted [
Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
[TBL] [Abstract][Full Text] [Related]
3. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
Bicak M; Lückerath K; Kalidindi T; Phelps ME; Strand SE; Morris MJ; Radu CG; Damoiseaux R; Peltola MT; Peekhaus N; Ho A; Veach D; Malmborg Hager AC; Larson SM; Lilja H; McDevitt MR; Klein RJ; Ulmert D
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15172-15181. PubMed ID: 32532924
[TBL] [Abstract][Full Text] [Related]
4. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.
McDevitt MR; Thorek DLJ; Hashimoto T; Gondo T; Veach DR; Sharma SK; Kalidindi TM; Abou DS; Watson PA; Beattie BJ; Timmermand OV; Strand SE; Lewis JS; Scardino PT; Scher HI; Lilja H; Larson SM; Ulmert D
Nat Commun; 2018 Apr; 9(1):1629. PubMed ID: 29691406
[TBL] [Abstract][Full Text] [Related]
5. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
Hanamura T; Christenson JL; O'Neill KI; Rosas E; Spoelstra NS; Williams MM; Richer JK
Breast Cancer Res; 2021 Nov; 23(1):102. PubMed ID: 34736512
[TBL] [Abstract][Full Text] [Related]
6. Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.
Feng J; Li L; Zhang N; Liu J; Zhang L; Gao H; Wang G; Li Y; Zhang Y; Li X; Liu D; Lu J; Huang B
Oncogene; 2017 May; 36(20):2775-2790. PubMed ID: 27893717
[TBL] [Abstract][Full Text] [Related]
7. Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines.
Magklara A; Grass L; Diamandis EP
Breast Cancer Res Treat; 2000 Feb; 59(3):263-70. PubMed ID: 10832596
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
Yoshida T; Jin K; Song H; Park S; Huso DL; Zhang Z; Liangfeng H; Zhu C; Bruchertseifer F; Morgenstern A; Sgouros G; Sukumar S
Oncotarget; 2016 May; 7(22):33306-15. PubMed ID: 27119227
[TBL] [Abstract][Full Text] [Related]
9. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
10. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
11. Wild-type and specific mutant androgen receptor mediates transcription via 17β-estradiol in sex hormone-sensitive cancer cells.
Susa T; Ikaga R; Kajitani T; Iizuka M; Okinaga H; Tamamori-Adachi M; Okazaki T
J Cell Physiol; 2015 Jul; 230(7):1594-606. PubMed ID: 25536295
[TBL] [Abstract][Full Text] [Related]
12. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
Peters AA; Buchanan G; Ricciardelli C; Bianco-Miotto T; Centenera MM; Harris JM; Jindal S; Segara D; Jia L; Moore NL; Henshall SM; Birrell SN; Coetzee GA; Sutherland RL; Butler LM; Tilley WD
Cancer Res; 2009 Aug; 69(15):6131-40. PubMed ID: 19638585
[TBL] [Abstract][Full Text] [Related]
14. PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates.
Veach DR; Storey CM; Lückerath K; Braun K; von Bodman C; Lamminmäki U; Kalidindi T; Strand SE; Strand J; Altai M; Damoiseaux R; Zanzonico P; Benabdallah N; Pankov D; Scher HI; Scardino P; Larson SM; Lilja H; McDevitt MR; Thorek DLJ; Ulmert D
Clin Cancer Res; 2021 Apr; 27(7):2050-2060. PubMed ID: 33441295
[TBL] [Abstract][Full Text] [Related]
15. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.
Moore NL; Buchanan G; Harris JM; Selth LA; Bianco-Miotto T; Hanson AR; Birrell SN; Butler LM; Hickey TE; Tilley WD
Endocr Relat Cancer; 2012 Aug; 19(4):599-613. PubMed ID: 22719059
[TBL] [Abstract][Full Text] [Related]
16. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
Yu Z; He S; Wang D; Patel HK; Miller CP; Brown JL; Hattersley G; Saeh JC
Clin Cancer Res; 2017 Dec; 23(24):7608-7620. PubMed ID: 28974548
[No Abstract] [Full Text] [Related]
17. A molecular analysis provides novel insights into androgen receptor signalling in breast cancer.
Mehta J; Asthana S; Mandal CC; Saxena S
PLoS One; 2015; 10(3):e0120622. PubMed ID: 25781993
[TBL] [Abstract][Full Text] [Related]
18. Androgens induce divergent proliferative responses in human breast cancer cell lines.
Birrell SN; Bentel JM; Hickey TE; Ricciardelli C; Weger MA; Horsfall DJ; Tilley WD
J Steroid Biochem Mol Biol; 1995 May; 52(5):459-67. PubMed ID: 7748811
[TBL] [Abstract][Full Text] [Related]
19. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
20. The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.
Makvandi M; Lieberman BP; LeGeyt B; Hou C; Mankoff DA; Mach RH; Pryma DA
Nucl Med Biol; 2016 Jan; 43(1):35-41. PubMed ID: 26702785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
